R207910
Jump to navigation
Jump to search
Introduction
New drug in clinical trials.
Indications
- treatment of Mycobacterium tuberculosis
Mechanism of action
- inhibits ATP synthase
- 10-fold greater bactericidal activity against M. tuberculosis than isoniazid or rifampin
More general terms
References
- ↑ Journal Watch 25(4):31-32, 2005 Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005 Jan 14;307(5707):223-7. Epub 2004 Dec 09. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15591164